SREBF2 and COVID-19: Briefly, SARS-CoV-2 infection disturbs cholesterol biosynthesis by activating SREBP-2 and affecting glucose or glutamine metabolism (50, 233) (Figures 2B-e, c, d). Clinical data has also indicated that lipid disorders may facilitate increased COVID-19 mediated pathogenicity, therefore lowering cholesterol levels may inhibit SARS-CoV-2 replication and viral loads in patients (51, 65).